

Researchers develop new smell test for Parkinson's, Alzheimer's and COVID-19

28 April 2021



Image of the novel capsule-based smell test. Credit: Queen Mary, University of London

A new smell test developed by Queen Mary University of London researchers has been found to be easy to use in patients with Parkinson's disease, and could also be helpful in diagnosing COVID-19 in the broader population.

Smell tests have the potential to support the diagnosis of certain neurological conditions, including Parkinson's and Alzheimer's. Unfortunately, these tests are not widely available, expensive, and take too long to administer in routine healthcare settings.

To address this problem, the team developed a novel smell testing kit which uses capsules of aromatic oils placed between two strips of singlesided tape.

To take the smell test, the capsules are simply crushed between the fingers and the tape strip peeled to release the aroma contained within the capsules. Based on a person's ability to recognize these smells, a score would be generated that can be sent to their GP if they are experiencing a loss

of smell.

Lead researcher Dr. Ahmed Ismail from Queen Mary's School of Engineering and Materials Science, said: "Our capsule-based smell test can assist in the rapid diagnostic of various diseases linked to the loss of smell. These include chronic neurological conditions such as Parkinson's and Alzheimer's disease, as well as COVID-19, which is known to affect the sense of smell.

"Being non-invasive and less stressful, the capsulebased smell test has benefits over the nose swab in diagnosing COVID-19. This is an advantage for testing children in particular, as they are typically horrified if they need to do a nose swab, and the test can be done in the comfort of their own home."

The study, published in the journal *Royal Society Interface*, showed that, in a small group of eight patients with Parkinson's disease, the smells from the tests were detectable. The participants also cited the relative ease process of rupturing the capsules, particularly for those with tremors, compared to the standard scratch and sniff smell test available on the market.

Dr. Ismail added: "Most of the smell tests on the market depend on using paperboard items treated with a fragrant coating called scratch and sniff, in which you need to scratch a card to release the odor. The problem with this approach is that the amount of odor released depends on the extent to which the individual scratches, something that might affect the outcome of the test.

"Our capsule-based <u>smell</u> test doesn't have this problem because the amount of odor released is controlled by the amount of oil precisely encapsulated. The mass-production of our new test would also be cheaper than a <u>scratch</u> and sniff <u>test</u>."

More information: A. Said Ismail et al. A novel



capsule-based smell test fabricated via coaxial dripping, *Journal of The Royal Society Interface* (2021). DOI: 10.1098/rsif.2021.0039

Provided by Queen Mary, University of London

APA citation: Researchers develop new smell test for Parkinson's, Alzheimer's and COVID-19 (2021, April 28) retrieved 9 July 2022 from <u>https://medicalxpress.com/news/2021-04-parkinson-alzheimer-covid-.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.